Efficacy of uric acid-lowering therapy on hypercholesterolemia and hypertriglyceridemia in gouty patients.
Efficacy of uric acid-lowering therapy on hypercholesterolemia and hypertriglyceridemia in gouty patients.
复制标题
降尿酸治疗对痛风患者高胆固醇血症和高甘油三酯血症的疗效。
DOI：
10.1111/1756-185x.13652
复制
发表时间：
2019
期刊：
影响因子：
--
通讯作者：
Qing‐Hong Yu
中科院分区：
文献类型：
--
作者：
Jing Wu;Yu‐Ping Zhang;Yuan Qu;Li‐Gang Jie;Qing‐Hong Yu
Abstract.Aim: To investigate the effects on hypercholesterolemia and hypertriglyceridemia in.gouty patients receiving uric acid‐lowering therapy (UALT)..Methods: A retrospective study was performed from January 2015 to December.2017 in gouty patients receiving UALT. A total of 124 gouty patients with hypercholesterolemia.or hypertriglyceridemia who were administered UALT were monitored..Of the 124 patients with gout, 52 were treated with febuxostat, 29 were treated with.allopurinol, and 43 were treated with benzbromarone. Cholesterol and triglyceride.levels were recorded and analyzed following treatment for 8‐10 weeks..Results: We compared the efficacy of febuxostat, allopurinol, and benzbromarone..All therapies mildly influenced serum cholesterol and triglyceride levels. Febuxostat.significantly decreased cholesterol and triglyceride levels in patients who did not.receive lipid‐lowering therapy. Allopurinol and benzbromarone modestly decreased.triglyceride levels, but cholesterol levels were unaffected..Conclusion: Uric acid‐lowering therapy benefits hyperlipidemia in gouty patients..Febuxostat effectively improved serum cholesterol and triglyceride levels compared.to allopurinol and benzbromarone in patients with gout.
